GenScript Partners With Tamarind Bio to Speed AI Drug Discovery Validation

GenScript Biotech Corporation and Tamarind Bio announced a strategic partnership on Tuesday to connect AI-powered molecular design with laboratory validation, giving researchers a streamlined workflow to move from computational designs to experimental testing.

The collaboration integrates Tamarind Bio's molecular design platform with GenScript's end-to-end wet-lab services, allowing researchers to submit AI-generated biological sequences directly for synthesis, expression, and testing. The companies said the workflow is designed to reduce manual handoffs between computational design and laboratory validation, helping research teams evaluate promising candidates more efficiently.

According to the announcement, GenScript's validation infrastructure can generate experimental data in as little as four days, enabling scientists to assess AI-generated molecules earlier in the drug discovery process. The company said its biologics expertise and laboratory capabilities are intended to help researchers generate higher-quality experimental datasets that can support downstream development decisions.

"AI is opening doors the industry could only imagine a few years ago," Ray Chen, President of GenScript Life Science Group, said. "But biology still determines what moves forward. By connecting AI-powered design to experimental proof, this partnership is helping lay the groundwork for the next generation of scientific innovation."